

Evrydiki Kravvariti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9254826/publications.pdf>

Version: 2024-02-01

18
papers

499
citations

949033

11
h-index

939365

18
g-index

18
all docs

18
docs citations

18
times ranked

862
citing authors

#	ARTICLE	IF	CITATIONS
1	Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3-year prospective study. <i>Rheumatology</i> , 2022, 61, 3408-3413.	0.9	12
2	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1013-1016.	0.5	43
3	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. <i>RMD Open</i> , 2022, 8, e002279.	1.8	18
4	Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166393.	1.8	4
5	Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e60-e60.	0.5	41
6	Clinical value of amyloid-beta1-40 as a marker of thrombo-inflammation in antiphospholipid syndrome. <i>Rheumatology</i> , 2021, 60, 1669-1675.	0.9	5
7	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. <i>Rheumatology International</i> , 2021, 41, 895-902.	1.5	15
8	The Relevance and Added Value of Geriatric Medicine (GM): Introducing GM to Non-Geriatricians. <i>Journal of Clinical Medicine</i> , 2021, 10, 3018.	1.0	12
9	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 1179.	2.1	7
10	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. <i>European Respiratory Journal</i> , 2021, 57, 2003021.	3.1	3
11	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. <i>Autoimmunity Reviews</i> , 2020, 19, 102491.	2.5	75
12	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 288.	0.3	9
13	Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. <i>Frontiers in Immunology</i> , 2019, 10, 487.	2.2	43
14	The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 63.	0.3	9
15	Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 883-889.	1.6	30
16	Nocebos in rheumatology: emerging concepts and their implications for clinical practice. <i>Nature Reviews Rheumatology</i> , 2018, 14, 727-740.	3.5	67
17	Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. <i>Rheumatology</i> , 2018, 57, 2158-2166.	0.9	23
18	Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 308-312.	2.5	83